232 related articles for article (PubMed ID: 35768621)
1. Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma.
Abrams RE; Pierre K; El-Murr N; Seung E; Wu L; Luna E; Mehta R; Li J; Larabi K; Ahmed M; Pelekanou V; Yang ZY; van de Velde H; Stamatelos SK
Sci Rep; 2022 Jun; 12(1):10976. PubMed ID: 35768621
[TBL] [Abstract][Full Text] [Related]
2. Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma.
Grab AL; Kim PS; John L; Bisht K; Wang H; Baumann A; Van de Velde H; Sarkar I; Shome D; Reichert P; Manta C; Gryzik S; Reijmers RM; Weinhold N; Raab MS
Cells; 2024 May; 13(10):. PubMed ID: 38786100
[TBL] [Abstract][Full Text] [Related]
3. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.
Keller AL; Reiman LT; Perez de Acha O; Parzych SE; Forsberg PA; Kim PS; Bisht K; Wang H; van de Velde H; Sherbenou DW
Cancer Res Commun; 2024 Mar; 4(3):757-764. PubMed ID: 38421887
[TBL] [Abstract][Full Text] [Related]
4. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement.
Chen L; Qian W; Pan F; Li D; Yu W; Tong L; Yang Y; Xu Q; Ding J; Dai R; Xian W; Zhu X; Ren P; Zhu H
Immunotherapy; 2024 Feb; 16(3):143-159. PubMed ID: 38126157
[TBL] [Abstract][Full Text] [Related]
5. Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.
Debelec-Butuner B; Quitt O; Schreiber S; Momburg F; Wisskirchen K; Protzer U
Front Immunol; 2022; 13():1029214. PubMed ID: 36405686
[TBL] [Abstract][Full Text] [Related]
6. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.
Wu L; Seung E; Xu L; Rao E; Lord DM; Wei RR; Cortez-Retamozo V; Ospina B; Posternak V; Ulinski G; Piepenhagen P; Francesconi E; El-Murr N; Beil C; Kirby P; Li A; Fretland J; Vicente R; Deng G; Dabdoubi T; Cameron B; Bertrand T; Ferrari P; Pouzieux S; Lemoine C; Prades C; Park A; Qiu H; Song Z; Zhang B; Sun F; Chiron M; Rao S; Radošević K; Yang ZY; Nabel GJ
Nat Cancer; 2020 Jan; 1(1):86-98. PubMed ID: 35121834
[TBL] [Abstract][Full Text] [Related]
7. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
8. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
9. Bispecific T-cell engagers for treatment of multiple myeloma.
Ravi G; Costa LJ
Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
[TBL] [Abstract][Full Text] [Related]
10. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.
Yoneyama T; Kim MS; Piatkov K; Wang H; Zhu AZX
PLoS Comput Biol; 2022 Jul; 18(7):e1009715. PubMed ID: 35839267
[TBL] [Abstract][Full Text] [Related]
11. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
[TBL] [Abstract][Full Text] [Related]
12. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
13. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
14. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
Song L; Xue J; Zhang J; Li S; Liu D; Zhou T
Eur J Pharm Sci; 2021 Mar; 158():105584. PubMed ID: 33039565
[TBL] [Abstract][Full Text] [Related]
16. Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma.
Fayon M; Martinez-Cingolani C; Abecassis A; Roders N; Nelson E; Choisy C; Talbot A; Bensussan A; Fermand JP; Arnulf B; Bories JC
Haematologica; 2021 Apr; 106(4):1193-1197. PubMed ID: 32675220
[No Abstract] [Full Text] [Related]
17. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Friedrich MJ; Neri P; Kehl N; Michel J; Steiger S; Kilian M; Leblay N; Maity R; Sankowski R; Lee H; Barakat E; Ahn S; Weinhold N; Rippe K; Bunse L; Platten M; Goldschmidt H; Müller-Tidow C; Raab MS; Bahlis NJ
Cancer Cell; 2023 Apr; 41(4):711-725.e6. PubMed ID: 36898378
[TBL] [Abstract][Full Text] [Related]
18. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications.
Letouzé E; Moreau P; Munshi N; Samur M; Minvielle S; Touzeau C
Blood Adv; 2024 Jun; 8(11):2952-2959. PubMed ID: 38513088
[TBL] [Abstract][Full Text] [Related]
20. eIg-based bispecific T-cell engagers targeting EGFR: Format matters.
Kühl L; Schäfer AK; Kraft S; Aschmoneit N; Kontermann RE; Seifert O
MAbs; 2023; 15(1):2183540. PubMed ID: 36864566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]